ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Wheeler, David C.*; Stefansson, Bergur, V; Jongs, Niels; Chertow, Glenn M.; Greene, Tom; Hou, Fan Fan; McMurray, John J., V; Correa-Rotter, Ricardo; Rossing, Peter; Toto, Robert D.; Sjostrom, C. David; Langkilde, Anna Maria; Heerspink, Hiddo J. L.南方医科大学
Lancet Diabetes & Endocrinology2021-1
258被引22阅读
引用收藏
分享

摘要

Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney, cardiovascular, and mortality outcomes according to presence or absence of type 2 diabetes and according to underlying cause of chronic kidney disease, reported as diabetic nephropathy, chronic glomenilonephritides, ischaemic or hypertensive chronic kidney disease, or chronic kidney disease of other or unknown cause. @@@ Methods DAPA-CKD was a multicentre, double-blind, placebo-controlled, randomised trial done at 386 study sites in 21 countries, in which participants with a urinary albumin-to-creatinine ratio of 200-5000 mg/g and an estimated glomerular filtration rate (eGFR) of 25-75 mL/min per 1.73m(2) were randomly assigned (1:1) to dapagliflozin 10 mg once daily or matching placebo, as an adjunct to standard care. The primary outcome was a composite of sustained decline in eGFR of at least 50%, end-stage kidney disease, or kidney-related or cardiovascular death. Secondary efficacy outcomes were a kidney-specific composite (the same as the primary outcome but excluding cardiovascular death), a composite of cardiovascular death or hospital admission for heart failure, and all-cause mortality. In this study, we conducted a prespecified subgroup analysis of the DAPA-CKD primary and secondary endpoints by presence or absence of type 2 diabetes and by aetiology of chronic kidney disease. DAPA-CKD is registered with ClinicalTrials.gov, NCT03036150. @@@ Findings The study took place between Feb 2, 2017, and June 12, 2020. 4304 participants were randomly assigned (2152 to dapagliflozin and 2152 to placebo) and were followed up for a median of 2.4 years (IQR 2.0-2.7). Overall, 2906 (68%) participants had a diagnosis of type 2 diabetes, of whom 396 (14%) had chronic kidney disease ascribed to causes other than diabetic nephropathy. The relative risk reduction for the primary composite outcome with dapagliflozin was consistent in participants with type 2 diabetes (hazard ratio [HR] 0.64, 95% CI 0.52-0.79) and those without diabetes (0.50, 0.35-0.72; p(interaction)=0.24). Similar findings were seen for the secondary outcomes: kidney-specific composite outcome (0.57 [0.45-0.73] vs 0.51 [0.34-0.75]; p(interaction)=0.57), cardiovascular death or hospital admission for heart failure (0.70 [0.53-0.92] vs 0.79 [0.40-1.55]; p(interaction)=0.78), and all-cause mortality (0.74 [0.56-0.98] vs 0.52 [0.29-0.93]; p(interaction)=0.25). The effect of dapagliflozin on the primary outcome was also consistent among patients with diabetic nephropathy (n=2510; HR 0.63, 95% CI 0-51-0-78), glomendonephritides (n=695; 0.43, 0.26-0.71), ischaemic or hypertensive chronic kidney disease (n=687; 0.75, 0.44-1.26), and chronic kidney disease of other or unknown cause (n=412; 0.58, 0-29-1.19; p(interaction)=0.53), with similar consistency seen across the secondary outcomes. The proportions of participants in the dapagliflozin and placebo groups who had serious adverse events or discontinued study drug due to adverse events did not vary between those with and those without type 2 diabetes. @@@ Interpretation Dapagliflozin reduces the risks of major adverse kidney and cardiovascular events and all-cause mortality in patients with diabetic and non-diabetic chronic kidney disease.

学科与关键词

关键词
OUTCOMESPROGRESSIONINHIBITIONBENAZEPRILRATIONALE
相关
加载中…
  • Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
    McMurray, John J. V.*; Wheeler, David C.; Stefansson, Bergur V.; Jongs, Niels; Postmus, Douwe; Correa-Rotter, Ricardo; Chertow, Glenn M.; Greene, Tom; Held, Claes; Hou, Fan-Fan; Mann, Johannes F. E.; Rossing, Peter; Sjostrom, C. David; Toto, Roberto D.; Langkilde, Anna Maria; Heerspink, Hiddo J. L.Circulation, 2021, 143(5): 438-448.被引 72
  • Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
    McMurray, John J., V*; Wheeler, David C.; Stefansson, Bergur, V; Jongs, Niels; Postmus, Douwe; Correa-Rotter, Ricardo; Chertow, Glenn M.; Hou, Fan Fan; Rossing, Peter; Sjostrom, C. David; Solomon, Scott D.; Toto, Robert D.; Langkilde, Anna Maria; Heerspink, Hiddo J. L.JACC-Heart Failure, 2021, 9(11): 807-820.被引 41
  • Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
    Persson, Frederik*; Rossing, Peter; Vart, Priya; Chertow, Glenn M.; Hou, Fan Fan; Jongs, Niels; McMurray, John J., V; Correa-Rotter, Ricardo; Bajaj, Harpreet S.; Stefansson, Bergur, V; Toto, Robert D.; Langkilde, Anna Maria; Wheeler, David C.; Heerspink, Hiddo J. L.Diabetes Care, 2021, 44(8): 1894-1897.被引 38
查看全部 →

发表信息

论文状态
公开发表
期刊
Lancet Diabetes & Endocrinology
发表日期
2021-01
卷期
第 9 卷, 第 1 期
页码
22-31
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
AstraZeneca

作者

  • W

    Wheeler, David C. (通讯) (第一作者)

  • S

    Stefansson, Bergur, V

查看全部 13 位作者收起作者
  • J

    Jongs, Niels

  • C

    Chertow, Glenn M.

  • G

    Greene, Tom

  • H

    Hou, Fan Fan

    southern med univ

  • M

    McMurray, John J., V

  • C

    Correa-Rotter, Ricardo

  • R

    Rossing, Peter

  • T

    Toto, Robert D.

  • S

    Sjostrom, C. David

  • L

    Langkilde, Anna Maria

  • H

    Heerspink, Hiddo J. L.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417